REMS Standardization Gets Boost From Lotronex Sticker Review
Executive Summary
FDA’s Drug Safety and Risk Management Advisory Committee endorses replacing paper-based verification system for the irritable bowel syndrome drug with an electronically integrated process that the agency seems to favor; the electronic system currently is used in the REMS for transmucosal immediate-release fentanyl products.
You may also be interested in...
Prometheus’ Lotronex REMS Could Lose Its Sticker Verification Requirement
FDA seeks advisory committee input on options for revising the irritable bowel syndrome drug’s Risk Evaluation and Mitigation Strategy, including eliminating a requirement for paper-based prescriptions and integrating the REMS into electronic pharmacy management systems.
Everything REMS Under The Sun: FDA Lays Out Ambitious PDUFA V Meeting Agenda
The struggles that industry and FDA face when trying to best standardize and evaluate REMS are illustrated by the dozens of topics jammed into the two-day meeting.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.